Osiris Therapeutics, Inc. (OSIR)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.00 / 19.30
Exchange NASDAQ
Div & Yield N.A. (N.A)
Osiris Therapeutics Announces First Quarter 2015 Financial Results

Osiris Therapeutics Announces First Quarter 2015 Financial Results

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

RSI Alert: Osiris Therapeutics (OSIR) Now Oversold

RSI Alert: Osiris Therapeutics (OSIR) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Osiris To Present Advanced Research On Chronic Wound Treatment Using Cryopreserved Placental Membranes

Osiris To Present Advanced Research On Chronic Wound Treatment Using Cryopreserved Placental Membranes

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present...

Osiris Therapeutics Announces First Quarter 2015 Financial Results Conference Call

Osiris Therapeutics Announces First Quarter 2015 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for first quarter ended March 31, 2015, on Friday, May 8, 2015.

Osiris Therapeutics Announces Alla Danilkovitch, Ph.D., As Chief Scientific Officer

Osiris Therapeutics Announces Alla Danilkovitch, Ph.D., As Chief Scientific Officer

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedic and sports medicine markets is...

Osiris Therapeutics To Present At The 3rd Annual Regen Med Investor Day

Osiris Therapeutics To Present At The 3rd Annual Regen Med Investor Day

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedic and sports medicine markets...

Commit To Purchase Osiris Therapeutics At $15, Earn 10% Annualized Using Options

Commit To Purchase Osiris Therapeutics At $15, Earn 10% Annualized Using Options

Investors considering a purchase of Osiris Therapeutics Inc shares, but tentative about paying the going market price of $17.61/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $15 strike, which has a bid at the time of this writing of 65 cents.

Osiris Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results: For The Full Year, Revenue Increased 146% And Company Reports Record Revenue In Fourth Quarter.

Osiris Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results: For The Full Year, Revenue Increased 146% And Company Reports Record Revenue In Fourth Quarter.

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris Therapeutics (OSIR) Upgraded From Sell to Hold

Osiris Therapeutics (OSIR) Upgraded From Sell to Hold

Osiris Therapeutics (OSIR) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CXO, DEPO, NEWT, OSIR, PRLB, TNAV Downgrades: AVIV, CRD.A, EHTH, MPW, QUAD Initiations: SC Read on to get TheStreet Quant Ratings' detailed report:

Osiris Therapeutics Announces Fourth Quarter And Full Year 2014 Financial Results Conference Call

Osiris Therapeutics Announces Fourth Quarter And Full Year 2014 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for fourth quarter and full year ended December 31, 2014, on Thursday, March 5, 2015.

Osiris Announces A Strategic Partnership With Stryker For Marketing Osiris' Viable Bone Matrix

Osiris Announces A Strategic Partnership With Stryker For Marketing Osiris' Viable Bone Matrix

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced...

Commit To Buy Osiris Therapeutics At $11, Earn 9.9% Annualized Using Options

Commit To Buy Osiris Therapeutics At $11, Earn 9.9% Annualized Using Options

Investors considering a purchase of Osiris Therapeutics Inc shares, but cautious about paying the going market price of $12.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2015 put at the $11 strike, which has a bid at the time of this writing of 45 cents.

Osiris Therapeutics Announces Expansion Of The Leadership Team

Osiris Therapeutics Announces Expansion Of The Leadership Team

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is pleased...

Osiris Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference

Osiris Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced ...

Osiris Therapeutics To Present At The Canaccord Genuity Medical Technology And Diagnostics Forum

Osiris Therapeutics To Present At The Canaccord Genuity Medical Technology And Diagnostics Forum

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris Therapeutics Announces Third Quarter 2014 Financial Results: Revenue Up 29% And Company Turned Profitable

Osiris Therapeutics Announces Third Quarter 2014 Financial Results: Revenue Up 29% And Company Turned Profitable

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedic and sports medicine,...

Osiris And Arthrex Announce An Exclusive Partnership For The Commercialization And Development Of Cartiform®

Osiris And Arthrex Announce An Exclusive Partnership For The Commercialization And Development Of Cartiform®

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris To Present Three Studies On Benefits Of Cryopreserved Placental Membranes For Chronic Wounds

Osiris To Present Three Studies On Benefits Of Cryopreserved Placental Membranes For Chronic Wounds

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will...

Osiris Therapeutics Announces Third Quarter 2014 Financial Results Conference Call

Osiris Therapeutics Announces Third Quarter 2014 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for third quarter ended September 30, 2014, on Friday, November 7, 2014.

Osiris Therapeutics To Present At The 2014 Stem Cell Meeting On The Mesa

Osiris Therapeutics To Present At The 2014 Stem Cell Meeting On The Mesa

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopedics and sports medicine markets, ...

Grafix® Featured In Plenary Session Oral Presentation At The Joint Annual Meeting Of The Eastern And New England Vascular Societies

Grafix® Featured In Plenary Session Oral Presentation At The Joint Annual Meeting Of The Eastern And New England Vascular Societies

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that data from an evaluation of Grafix in the treatment of chronic venous leg ulcers (VLUs) was presented on Sunday September 14 th, at the joint annual...

Grafix® Randomized Controlled Clinical Trial Recognized As High Quality DFU Trial In Recent Wounds Supplement

Grafix® Randomized Controlled Clinical Trial Recognized As High Quality DFU Trial In Recent Wounds Supplement

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today the release of a dedicated supplement in Wounds, a peer-reviewed journal focusing on wound care and wound research, based on the proceedings of a CME ...

Commit To Buy Osiris Therapeutics At $12, Earn 10.4% Annualized Using Options

Commit To Buy Osiris Therapeutics At $12, Earn 10.4% Annualized Using Options

Investors eyeing a purchase of Osiris Therapeutics Inc stock, but cautious about paying the going market price of $14.77/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2015 put at the $12 strike, which has a bid at the time of this writing of 65 cents.

5 Unusual Stocks Moving on Unusual Volume

5 Unusual Stocks Moving on Unusual Volume

Keep these stocks rising on unusual volume on your trading radar.

Osiris Therapeutics Announces Second Quarter 2014 Financial Results: Revenue Up 32% Over Previous Quarter

Osiris Therapeutics Announces Second Quarter 2014 Financial Results: Revenue Up 32% Over Previous Quarter

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced today its financial results for ...

Grafix® Manuscript From Osiris’ Multi-center, Randomized, Controlled Clinical Trial Available Electronically In Peer-Reviewed Journal

Grafix® Manuscript From Osiris’ Multi-center, Randomized, Controlled Clinical Trial Available Electronically In Peer-Reviewed Journal

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that the manuscript from its multi-center (n=20), randomized, controlled clinical trial comparing the safety and effectiveness of Grafix® to control in ...

Osiris Expands Its Grafix® Product Portfolio And Launches Additional Sizes

Osiris Expands Its Grafix® Product Portfolio And Launches Additional Sizes

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced the addition of several new sizes to the Grafix® product line.

Osiris Therapeutics Announces Second Quarter 2014 Financial Results Conference Call

Osiris Therapeutics Announces Second Quarter 2014 Financial Results Conference Call

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for second quarter ended June 30, 2014, on Thursday, August 7, 2014.